Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: An integrated parent-metabolite model

Pharmaceutical Research

Volumn 22, Issue 11, 2005, Pages 1769-1782

  Ortega, Fátima ^a,b   Quintana, Antonio ^a   Suárez, Elena ^a   Lukas, John C ^a,c   Jauregizar, Nerea ^d   De La Fuente, Leire ^d   Lucero, Maria Luisa ^e   Gonzalo, Ana ^e   Orjales, Aurelio ^e   Calvo, Rosario ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Dynakin SL   (Spain)

^c PHARSIGHT CORPORATION   (United States)

^d SLL   (Spain)

^e FAES FARMA SA   (Spain)

Author keywords

Integrated parent metabolite model; Lerisetron; Metabolite; Pharmacokinetic

Indexed keywords

DRUG METABOLITE; LERISETRON; LERISETRON DERIVATIVE; PROTEIN; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW; BRADYCARDIA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; FECES; IN VIVO STUDY; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN BINDING; RAT; ULTRAFILTRATION;

ANIMALS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HYDROXYLATION; MALE; MODELS, BIOLOGICAL; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN ANTAGONISTS;

EID: 27144506547     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-005-7750-6     Document Type: Article

References (29)

1. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting Cancer Invest. 18 163 173
2. 3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile The Oncologist 7 424 436
3. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy Drugs 55 173 189
4. Y. E. Yarker D. G. McTavish 1994 Granisetron: An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy Drugs 48 761 793
5. V. Fischer J. P. Baldeck F. L. S. Tse 1992 Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans Drug Metab. Dispos. 20 603 607
6. 3 receptor antagonist Drug Metab. Dispos. 23 806 812
7. N. D. Evans K. R. Godfrey M. J. Chapman M. J. Chappell L. Aarons S. B. Duffull 2001 An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine J. Pharmacokinet. Pharmacodyn. 28 93 105
8. M. Rowland T. N. Tozer 1995 Clinical Pharmacokinetics: Concepts and Applications 3 Williams & Wilkins, Media Pennsylvania 367 393
9. 3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers Arzneim-Forsch./Drug Res. 52 689 694
10. 3 antagonists. Synthesis and pharmacological evaluations J. Med. Chem. 40 586 593
11. J. R. Fozard M. Host 1982 Selective inhibition of the Bezold-Jarisch effect of 5-HT in the rat by antagonists at neuronal 5-HT receptors Br. J. Pharmacol. 77 520p
12. M. Yamano T. Kamato A. Nishida H. Ito H. Yuki R. Tsutsumi K. Honda K. Miyata 1994 Serotonin (5-HT) receptor antagonism of 4, 5, 6, 7-tetrahydrobenzimidazole derivatives against 5-HT induced bradycardia in anesthetized rats Jpn. J. Pharmacol. 65 241 248
13. N. Jauregizar R. Calvo E. Suárez A. Quintana E. Raczka J. C. Lukas 2001 Altered disposition and effect of lerisetron in rats with elevated alpha1-acid glycoprotein levels Pharm. Res. 18 838 845
14. 3 antagonist, in rats J. Pharm. Sci. 91 41 52
15. N. Jauregizar A. Quintana E. Suarez E. Raczka L. de la Fuente R. Calvo 2003 Age-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: a population pharmacokinetic model Gerontology 49 205 214
16. V. P. Shah K. K. Midha J. W. A. Findlay H. M. Hill J. D. Hulse I. J. McGilveray G. Mckay K. J. Miller R. N. Patnaik M. L. Powell A. Tonelli C. T. Viswanathan A. Yacobi 2000 Bioanalytical Methods validation-a revisit with a decade of progress Pharm. Res. 17 1551 1557
17. 3 antagonist, in patients with cancer Cancer Chemother. Pharmacol. 42 418 422
18. L. B. Sheiner S. L. Beal 1981 Some suggestions for measuring predictive performance J. Pharmacokinet. Biopharm. 9 503 512
19. K. P. Zuideveld J. Rusiç-Pavletiç H. J. Maas L. A. Peletier P. H. Van Der Der Graaf M. Danhof 2002 Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats J. Pharmacol. Exp. Ther. 303 1130 1137
20. D. K. Walker 2004 The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development Br. J. Clin. Pharmacol. 58 601 608
21. D. A. Saynor C. M. Dixon 1989 The metabolism of ondansetron Eur. J. Clin. Oncol. 25 Suppl 1 S75 S77
22. C. M. Dixon P. V. Colthup C. J. Serabjit-Singh B. M. Kerr C. C. Boehlert G. R. Park M. H. Tarbit 1995 Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans Drug Metab. Dispos. 23 1225 1230
23. M. T. Serafini S. Puig G. Garcia-Encina R. Farran A. Garcia-Soret T. Moragon L. Martínez 1997 Absorption, distribution and excretion of [14C]-lesopitron after single and repeated administration in rats and dogs Methods Find. Exp. Clin. Pharmacol. 19 61 72
24. J. H. Lin M. Yamazaki 2003 Role of P-glycoprotein in pharmacokinetics. Clinical implications Clin. Pharmacokinet. 42 59 98
25. 3 receptor antagonist, across the blood-brain barrier J. Pharm. Pharmacol. 54 1055 1063
26. B. Tuk M. F. Van Oostenbruggen V. M. M. Herben J. W. Mandema M. Danhof 1999 Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: Midazolam and α-OH-midazolam J. Pharmacol. Exp. Ther. 289 1067 1074
27. J. Lötsch C. Skarke H. Schmidt J. Liefhold G. Geisslinger 2002 Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers Clin. Pharmacol. Ther. 72 151 162
28. B. P. Murthy G. M. Pollack K. L. R. Brouwer 2002 Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers J. Clin. Pharmacol. 42 569 576
29. S. B. Martin M. Rowland 1973 Determination of tolbutamideandmetabolites in biological fluids Anal. Lett. 6 865 876